Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Post : Deputy Manager (Qms) - Qa (Tablet Formulation)

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Post : Production

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

PRODUCTION (TABLET FORMULATION)

Indoco Remedies Ltd. headquartered in India, is a fast growing, fully integrated, research oriented pharmaceutical company with a Global presence, Indoco manufactures a wide range of pharmaceutical products in various therapeutic segments for Indian and International markets. Indoco has state-of-art world class manufacturing facilities which have been awarded by World Regulatory Authorities like US-FDA, MHRA – UK. Darmstadt-Germany, MCC and ANVISA-Brazil.

For our manufacturing facilities at Goa, we require

Post: Officers, Executives, Assistant Manager

Indoco Remedies Ltd. has received the Establishment Inspection Report (approval) from US Food and Drug Administration (USFDA) for its solid dosages manufacturing facility at Goa (Plant I), thereby confirming the closure of inspection in October, 2015.

Indoco Remedies, has posted its standalone net profit during the fourth quarter ended March 2015 to Rs.18.75 crore from Rs.18.55 crore in the corresponding quarter of last year due to higher R&D expenditure. Its R&D expenditure increased by 78.2 per cent to Rs.7.45 crore from Rs.4.18 crore. The company's standalone net sales increased by 13.8 per cent to Rs.211.59 crore from Rs.185.86 crore. Its EBIDTA moved up by 11.2 per cent to Rs.37.66 crore from Rs.33.88 crore. EPS remained almost same at Rs.2.03.  The board of directors has recommended equity dividend of 80 per cent i.e. Rs.1.60 per share for the year 2014-15.